Disparities in the Prevalence, Pathogenesis and Progression of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Between Blacks and Whites

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2011 Dec 24

PMID 22193966

Citations 41

Authors

A J Greenberg

C M Vachon

S V Rajkumar

Affiliations

Soon will be listed here.

Abstract

There is marked racial disparity in the incidence of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma, with a two to threefold increased risk in blacks compared with whites. The increased risk has been seen both in Africans and African Americans. Similarly, an increased risk of monoclonal gammopathies in blacks compared with whites has been noted after adjusting for socioeconomic and other risk factors, suggesting a genetic predisposition. The higher risk of multiple myeloma in blacks is likely a result of the higher prevalence of the premalignant MGUS stage; there are no data to suggest that blacks have a higher progression rate of MGUS to myeloma. Studies are emerging that suggest the baseline cytogenetic characteristics, and progression may differ by race. In contrast, to the increased risk noted in blacks, studies suggest that the risk may be lower in certain racial and ethnic groups, notably persons from Japan and Mexico. We review the literature on racial disparity in the prevalence, pathogenesis and progression of MGUS and multiple myeloma between blacks and whites. We also discuss future directions for research that could inform management of these conditions and positively influence patient outcomes.

Citing Articles

Germline predisposition in multiple myeloma.

Rodrigues F, Jasielec J, Perpich M, Kim A, Moma L, Li Y iScience. 2025; 28(1):111620.

PMID: 39845416 PMC: 11750583. DOI: 10.1016/j.isci.2024.111620.

Disparity in the detection of chromosome 15 centromere in patients of African ancestry with a plasma cell neoplasm.

Koleilat A, Tang H, Sharma N, Yan H, Tian S, Smadbeck J Genet Med Open. 2024; 1(1):100816.

PMID: 39669246 PMC: 11613710. DOI: 10.1016/j.gimo.2023.100816.

Asymptomatic Incidence of Monoclonal Gammopathy of Undetermined Significance and Preclinical Duration to Myeloma Diagnosis: A Modeling Study.

Ji M, Shih Y, Huber J, Wang M, Feuer E, Etzioni R Cancer Epidemiol Biomarkers Prev. 2024; 33(12):1690-1697.

PMID: 39106151 PMC: 11611677. DOI: 10.1158/1055-9965.EPI-24-0490.

Multiple myeloma incidence and mortality trends in the United States, 1999-2020.

Zhu D, Park A, Lai A, Zhang L, Attar H, Rebbeck T Sci Rep. 2024; 14(1):14564.

PMID: 38914692 PMC: 11196710. DOI: 10.1038/s41598-024-65590-4.

Approaches to developing de novo cancer population models to examine questions about cancer and race in bladder, gastric, and endometrial cancer and multiple myeloma: the Cancer Intervention and Surveillance Modeling Network incubator program.

Sereda Y, Alarid-Escudero F, Bickell N, Chang S, Colditz G, Hur C J Natl Cancer Inst Monogr. 2023; 2023(62):219-230.

PMID: 37947329 PMC: 11009510. DOI: 10.1093/jncimonographs/lgad021.

References

Baris D, Brown L, Silverman D, Hayes R, Hoover R, Swanson G . Socioeconomic status and multiple myeloma among US blacks and whites. Am J Public Health. 2000; 90(8):1277-81. PMC: 1446323. DOI: 10.2105/ajph.90.8.1277. View

Landgren O, Gridley G, Turesson I, Caporaso N, Goldin L, Baris D . Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2005; 107(3):904-6. PMC: 1895893. DOI: 10.1182/blood-2005-08-3449. View

Brown L, Linet M, Greenberg R, Silverman D, Hayes R, Swanson G . Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer. 1999; 85(11):2385-90. View

Patel M, Wadee A, Galpin J, Gavalakis C, Fourie A, Kuschke R . HLA class I and class II antigens associated with multiple myeloma in southern Africa. Clin Lab Haematol. 2002; 24(4):215-9. DOI: 10.1046/j.1365-2257.2002.00448.x. View

Landgren O, Katzmann J, Hsing A, Pfeiffer R, Kyle R, Yeboah E . Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007; 82(12):1468-73. DOI: 10.1016/S0025-6196(11)61089-6. View

Modiano M, Crowley J, Salmon S . Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. J Clin Oncol. 1996; 14(3):974-7. DOI: 10.1200/JCO.1996.14.3.974. View

Lynch H, Ferrara K, Barlogie B, Coleman E, Lynch J, Weisenburger D . Familial myeloma. N Engl J Med. 2008; 359(2):152-7. PMC: 2775509. DOI: 10.1056/NEJMoa0708704. View

Gorini G, Stagnaro E, Fontana V, Miligi L, Ramazzotti V, Amadori D . Alcohol consumption and risk of Hodgkin's lymphoma and multiple myeloma: a multicentre case-control study. Ann Oncol. 2006; 18(1):143-148. DOI: 10.1093/annonc/mdl352. View

Waxman A, Mink P, Devesa S, Anderson W, Weiss B, Kristinsson S . Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010; 116(25):5501-6. PMC: 3031400. DOI: 10.1182/blood-2010-07-298760. View

10.

Landgren O, Weiss B . Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009; 23(10):1691-7. DOI: 10.1038/leu.2009.134. View

11.

Brown L, Gridley G, Check D, Landgren O . Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 2008; 111(7):3388-94. PMC: 2275008. DOI: 10.1182/blood-2007-10-121285. View

12.

Benjamin M, Reddy S, Brawley O . Myeloma and race: a review of the literature. Cancer Metastasis Rev. 2003; 22(1):87-93. DOI: 10.1023/a:1022268103136. View

13.

Johnston D, Lee W . Explaining the female black-white obesity gap: a decomposition analysis of proximal causes. Demography. 2011; 48(4):1429-50. DOI: 10.1007/s13524-011-0064-x. View

14.

Blade J, Rosinol L, Cibeira M, de Larrea C . Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia. 2008; 22(9):1651-7. DOI: 10.1038/leu.2008.203. View

15.

Cohen H, Crawford J, Rao M, Pieper C, Currie M . Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med. 1998; 104(5):439-44. DOI: 10.1016/s0002-9343(98)00080-1. View

16.

Gebregziabher M, Bernstein L, Wang Y, Cozen W . Risk patterns of multiple myeloma in Los Angeles County, 1972-1999 (United States). Cancer Causes Control. 2006; 17(7):931-8. DOI: 10.1007/s10552-006-0030-x. View

17.

Kyle R, Therneau T, Rajkumar S, Larson D, Plevak M, Offord J . Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006; 354(13):1362-9. DOI: 10.1056/NEJMoa054494. View

18.

Rosinol L, Cibeira M, Montoto S, Rozman M, Esteve J, Filella X . Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc. 2007; 82(4):428-34. DOI: 10.4065/82.4.428. View

19.

Rajkumar S, Kyle R, Therneau T, Melton 3rd L, Bradwell A, Clark R . Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005; 106(3):812-7. PMC: 1895159. DOI: 10.1182/blood-2005-03-1038. View

20.

. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121(5):749-57. View